

Ira David Glick, MD
Pacific Research Partners, LLC
1611 Telegraph Avenue, Suite 100 & Suite 1550
Oakland, CA 94612

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Site Liaison
Tel. (866) 669-0234
Fax (208) 575-3169
Email: clinicaltrials@btheodore.com

AFFILIATIONS:

Collaborative Neuroscience Network, Inc.
12772 Valley View Street, Suite 3
Garden Grove, CA 92845

Collaborative Neuroscience Network, Inc.
2600 Redondo Avenue, Suite 500
Long Beach, CA 90806

Collaborative Neuroscience Network, Inc.
19401 S. Vermont Avenue, Suite F-100
Torrance, CA 90502

Stanford University Medical Hospital

EDUCATION:

1957 B.S., Dickinson College, Carlisle, Pennsylvania
1961 M.D., New York Medical College

INTERSHIPS AND RESIDENCIES:

1965-1966 Candidate, New York Psychoanalytic Institute, New York, NY
1961-1962 Rotating Internship, Beth Israel Hospital, New York, NY
1962-1966 Psychiatry Residency:
1962-1963 First Year Resident, Hillside Hospital, Glen Oaks, New York
1963-1964 Second Year Resident, Mt. Zion Hospital, San Francisco, CA
1964-1965 Chief Resident, Hillside Hospital

LICENSURE:

1962-1993 New York State Medical License
1963- California State Medical License - (G 9084)
1963- Diplomate of the National Board of Medical Examiners
1968- Diplomate of the American Board of Psychiatry and Neurology
1980- Mental Health Administrator, Commission on Certification in
Administrative Psychiatry of the American Psychiatric Association
1988-1990 Maryland Medical License
(License number available on request)

PROFESSIONAL EXPERIENCE:

Principle Investigator, 2010- Present
Pacific Research Partners, Oakland, CA

Director, Schizophrenia Research Clinic, 1993 – Present
Stanford University School of Medicine & Stanford University Hospital

Director of Inpatient & Partial Hospitalization Services, 1993 - 2000
Stanford University School of Medicine & Stanford University Hospital

Acting Deputy Chief of Staff and Chief of Psychiatry, 1995 - 1996
Veterans Administration Hospital, Palo Alto, CA

Associate Medical Director, 1978-1993
Payne Whitney Clinic, Department of Psychiatry, The New York Hospital

Senior Science Advisor to the Director, 1988-1990
National Institute of Mental Health, Rockville, MD

Director, Inpatient Services, 1978-1988
Director, of the Family Therapy Program, 1978-1993
Director, Outpatient Department, 1990-1993
Cornell Medical Center

Chief, Clinical Research Ward, 1968-1978
(Renamed the Inpatient Treatment & Research Service, 5/1/75)
Director, Medical Student Education, 1975-1978
Langley Porter Neuropsychiatric Institute and Dept. of Psychiatry, School of Medicine
University of California, San Francisco

Service Record: *Captain*, Army of the United States, *Chief*, Psychiatry Service, 1966-1968
U.S. Army Hospital Specialized Treatment Center, Fort Gordon, Georgia

PROFESSIONAL EXPERIENCE (continued) :

Staff Psychiatrist and Research Associate, 1965-1966
Hillside Hospital, Glen Oaks, New York

INVESTIGATOR EXPERIENCE:

Adolescent Psychiatry • Attention Deficit Hyperactivity Disorder (ADHD)
Alzheimer's Disease • Anxiety • Bipolar Disorder
Depression • Insomnia • Schizophrenia • Mania

INTEREST:

Dementia • Alzheimer's Disease • ADHD • Sleep Disorders • Anxiety

CLINICAL TRIAL EXPERIENCE:

Depression

A Phase III, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of XXX in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant

A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 mg XXX versus Placebo in Adult Subjects with Major Depressive Disorder Followed by a 52-week Open-label Extension

A Phase III, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of XXX in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant

A Phase IV, Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy of Two Fixed Doses (50 and 100 MG/Day) of XXX in Adult Outpatients with Major Depressive Disorder (MDD)

A Phase III, , Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Efficacy and Safety Study of 3 Fixed Dose Groups of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy.

A Phase III, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of XXX in Subjects With Major Depressive Disorder

CLINICAL TRIAL EXPERIENCE (continued):

A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of XXX in Acute Treatment of Adults With Major Depressive Disorder

A Phase III, Randomized Placebo-Controlled, Double-Blind Study of XXX Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to XXX Treatment.

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of XXX in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy.

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy

Schizophrenia

A Phase III, Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with XXX Compared with 6-month Retrospective Treatment with Oral Antipsychotics in a Naturalistic Community Setting in the United States

A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of XXX Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Recently Released From Jail

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia

A Multicenter, Double-Blind Comparison of XXX and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with XXX

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of XXX in the Treatment of Adults With Acute Schizophrenia

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of XXX versus Placebo in Patients with DSM-IV-TR Schizophrenia

A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

CLINICAL TRIAL EXPERIENCE (continued):

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXX Evaluating Time to Relapse in Subjects With Schizoaffective Disorder

A Randomized, 6-week, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of XXX for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects SWITCHED From Other Antipsychotic Agents *and* A 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to XXX for the Treatment of Schizophrenia or Schizoaffective Disorder

A 12-week, Randomized, Multicenter, Open-label, XXX Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving XXX or XXX

FUNDED RESEARCH ACTIVITIES:

2009 Educational Outreach Initiative Grant

2008 XXX, A Multi-center, Double-Blind, Randomized, Active-Controlled, Study to Evaluate the Long-term Efficacy, Safety and Tolerability of an Intramuscular Depot Formulation of XXX in Patients with Schizophrenia

2008 Schizophrenia Trials Network associated with NIMH Contract
XXX Comparison of Optimal Antipsychotic Treatment for Schizophrenia (COATS: A Pilot Study) XXX in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS: A Pilot Study)

2008 Keeping Up With Advances in Psychopharmacology in the New Millenium, four lectures at medical schools in Israel, supported by the Sarlo Fund and the Ingrid D. Tauber Philanthropic Fund from the Jewish Community Endowment Fund, San Francisco, June, 2008.

2008 XXX, Validation of the Reasons for Antipsychotic Discontinuation/Continuation Questionnaire (RAD-Q) and Interview (RAD-I)

2007 A Six Week, Double-Blind, Placebo-Controlled Phase III Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Flexible Doses of Oral XXX in Adolescents with Schizophrenia.

2007 XXX, A Randomized, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect Of XXX Versus XXX In Patients With Schizophrenia Using the XXX

2007 American College of Neuropsychopharmacology, ACNP Public Outreach Initiative. 2007 Schizophrenia Education Day. (also supported by XXX)

FUNDED RESEARCH ACTIVITIES (continued):

- 2006 XXX, An Open-Label Study of Equetro in Outpatients with Aggressive Symptoms & Behavior (investigator initiated study)
- 2006 XXX, A Multi-center, Randomized, Double-Blind, Placebo-Controlled, 16-week Study of XXX Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to XXX Monotherapy.
- 2006 XXX, A Multi-center, Double-Blind, Flexible-Dose, 6-month Trial Comparing the Efficacy and Safety of XXX in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia.
- 2006 CAMP (Foundation for NIH), Clinical Management of Metabolic Problems in Patients with Schizophrenia: Switching to XXX vs. XXX
- 2005 American College of Neuropsychopharmacology, ACNP Public Outreach Program
- 2005 XXX vs. XXX Double Blind. (investigator initiated Study)
- 2005 XXX, Parallel-Group Efficacy and Safety Study of Two Fixed Doses of XXX in the Treatment of Schizophrenia.
- 2005 Co-Investigator of a XXX Grant for a project Fostering Collaboration Through Clinical Education: A Clinical Neurosciences Seminar, Clinic and Curriculum Series in Child Psychiatry and Pediatric Neurology (with Joshi SV, Chang KD and Hahn J).
- 2004 XXX Education Fund
- 2004 XXX, Comparison of Atypicals for First Episode (CAFE)
- 2004 XXX, The Treatment of Schizophrenia and OCD Symptomatology with XXX (investigator-initiated study).
- 2004 Pfizer, Zodiac International Schizophrenia Study to Compare the Cardiovascular Safety of XXX and XXX.
- 2003 XXX, A 12 Week Multicenter, Randomized, Double-Blind, Placebo Controlled Evaluation of XXX as Adjunctive Therapy in the Treatment of Cognitive Impairment in Patient with Schizophrenia or Schizoaffective Disorder

FUNDED RESEARCH ACTIVITIES (continued):

- 2003 XXX, Efficacy and Weight Reduction Effects of XXX in Stabilized Patients with Schizophrenia and Weight Associated with Atypical Antipsychotics (investigator initiated study with Reaven).
- 2003 XXX, An Open-Label Follow-Up Study of the Long-Term Safety of XXX in Patients with Psychosis.
- 2001 XXX, A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Flexible Doses of XXX Versus XXX In the Treatment of Patients with Treatment-Resistant Schizophrenia
- 2000 National Institute of Mental Health, sub-contract , Comparative Effectiveness of Antipsychotic Medications in Patients with Schizophrenia CATIE: Human Genetics Initiative
- 1999 XXX, XXX vs. Placebo in the Treatment of Subjects with Schizophrenia or Schizoaffective Disorder
- 1999 Development of a Model Psychopharmacology Curriculum for Psychiatric Residents. (through the American Society of Clinical Psychopharmacology) Supported in part by XXX
- 1998 XXX Corporation, A Prospective, Randomized, International, Parallel-group Comparison of XXX vs. XXX in the Reduction of Suicidality in Patients with Schizophrenia or Schizoaffective Disorder Who Are at Risk for Suicide
- 1998 Research Grant for the investigator initiated study, XXX vs XXX for the Long-Term Treatment of Schizophrenia and Schizoaffective Disorder with Marder S.
- 1998 XXX, The Acute and Long-Term Efficacy of XXX in First-Episode Psychotic Disorders: A Randomized Double-Blind Comparison with XXX
- 1998 XXX Pharmaceuticals, A Multi-Center, Placebo Controlled Double Blind Study Comparing the Safety and Efficacy of XXX with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care
- 1997 XXX Research Grant for the study, A Multi-center, Randomized, Double-Blind, Placebo and Active Controlled Study of XXX in Schizophrenic and Schizoaffective Patients
- 1997 XXX Research Grant for the study, A Phase III Double-Blind Placebo-Controlled Study of XXX in the Treatment of Psychosis, with XXX as Active Control

FUNDED RESEARCH ACTIVITIES (continued):

- 1996 XXX Research Grant for the study, A Multi-center, Open, Randomized Comparison of and Usual Care on Health Outcomes in Subjects with Schizophrenia and Schizoaffective Disorder
- 1995 XXX Unrestricted grant to develop a Model Psychopharmacology Curriculum for Residents (Committee Chair) under the auspices of the American Society of Clinical Psychopharmacology
- 1995 XXX Research Grant for the study, XXX versus XXX in the Treatment of Schizophrenia and other Psychotic Disorders
- 1995 XXX Grant for the study, Dose-Response Study in the Treatment of Negative Symptoms of Schizophrenia with XXX
- 1995 XXX Research Grant for the study, A Comparative Cost Effectiveness Study of XXX and Usual Care versus XXX and Usual Care in the Treatment of Bipolar Disorder
- 1993 (Stanford) A Double-Blind, Haldol-Referenced, Placebo-Controlled Study
- 1993 Pharmacologic Medication Discovery & Development Project (PMDDP) Supported by XXX
- 1993 XXX for the Study, Treatment of Adolescent Depression with XXX
- 1993 XXX Grant for the study, Safety and Efficacy of XXX in the Prevention of Mania in Patients With Bipolar Disorder
- 1992-1995 National Institute of Mental Health Grant, Marital Treatment for Bipolar Disorder Patients, Co-Principal Investigator with John Clarkin, PhD, P.I.
- 1992 (Cornell) XXX Research Grant for the study: XXX in the & Prevention of Mania
- 1992 XXX Research Grant for the study: XXX for the Treatment of Schizophrenia and Schizoaffective Disorder
- 1992 (Cornell) XXX Research Grant for the study: The Safety and Efficacy of XXX in Schizophrenic Patients
- 1991 XXX Grant for the study, XXX in the Treatment of the Negative Symptoms of Schizophrenia
- 1987 XXX Research Award for the project, Delivery and Compliance to Good Medical Treatment

FUNDED RESEARCH ACTIVITIES (continued):

1984-1986 National Institute of Mental Health Grant for project Inpatient Family Intervention: Evaluation of Practice

1984-1993 National Institute of Mental Health, Cooperative Clinical Agreement Award for the project, Treatment Strategies in Schizophrenia, 1982-1983 National Institute of Mental Health - Biomedical Research Support Grant for the study Inpatient Family Intervention: A Controlled Study

1982-1983 National Institute of Mental Health Contract -to develop a Model Psychopharmacology Curriculum for Psychiatric Residency Training (with David Janowsky MD) under the auspices of the American College of Neuropsychopharmacology

1977-1978 Endo Research Grant for the study XXX vs. XXX: Double Blind Investigation of the Treatment of Acute Schizophrenia

1977-1982 National Institute of Mental Health Grant for Medical Student Psychiatric Education,

1977-1978 Vice Chancellor's Advisory Committee on Instructional Improvements Grant, UCSF, for project Effectiveness and Efficiency in Small Group Teaching with Mary Malloy, MD

1975-1977 Lederle Research Grant for the study XXX Treatment in Schizophrenia

1971-1975 National Institute of Mental Health Grant for the project XXXShort vs. Long Psychiatric Hospitalization: A Controlled Study

1965-1966 G.D. Searle Research Grant for the study: Pseudopregnancy Treatment of Periodic Psychiatric Illness

EDITORIAL AND ADVISORY BOARDS:

- 2009 - Advisory Board, Pfizer. Anxiety Disorders
- 2008 - Editorial Board, The Physician and Sports Medicine
- 2005 - Editorial Board, The Journal of Clinical Psychiatry
- 2002, 03',04',05' Advisory Board, Bristol-Myers Squibb California Neuroscience
- 2002, 04',05' Advisory Board, Shire Pharmaceuticals
- 2001 - Board of Directors, National Foundation for Depressive Illness, Inc
- 2001, 2005 Advisory Board, Pfizer (Geodon) Pharmaceuticals
- 1999 - Advisory Board, NPSP Pharmaceuticals Bipolar Clinical Advisory Board, Boca Raton
- 1999 - Advisory Board, Hoechst Marion Roussel (Aventis)

EDITORIAL AND ADVISORY BOARDS (continued):

- 1998 - Advisory Board, Otsuka Pharmaceuticals
1997 - Advisory Board, Zeneca Pharmaceuticals
1997- 1999 Advisory Board, Janssen Pharmaceutica and Research Foundation
1997- 1999 Advisory Board, Institute for Healthcare Quality, Minneapolis
1996 - CNS Science Advisory Board, Wyeth Ayerst Pharmaceutical
1995-1997 Gralnick Foundation Awards Committee
1993 - Board Member, The National Mental Health Project
1993 - Sertindole Advisory Board, , Neuroscience Venture, Abbott Laboratories
1990 -1992 Advisory Board, MultiMedia Reviews in Psychiatry , Massachusetts General Hospital.
1989 - Progress in Neuropsychology and Biological Psychiatry
1984-1987 National Council of Advisors on Development and External Affairs, UCSF
1984-1997 The Journal of Family Psychotherapy
1982-1995 Board of Advisors, Dickinson College
1982 - The Journal of Family Therapy (England)
1981 - Journal of Clinical Psychopharmacology
1981 - Contemporary Family Therapy - An International Journal
1970-1981 Family Process

AWARDS:

2010 National Alliance on Mental Illness (NAMI) exemplary (I don't think this is a word) Psychiatrist Awards

2008 The American College of Psychiatrists' (ACP) Distinguished Service in Psychiatry Award, one award given each year to recognize distinguished achievements and leadership in the field of psychiatry.

2008 The Association for Academic Psychiatry, Distinguished Life Fellow, given each year for mastery in a career dedicated to educational endeavors, demonstrated generativity (this one either...I think we need to check it) by unselfishly guiding the next generation of academic psychiatrists, and engaged in passing on the traditions of the past to the next generation of academic psychiatrists

2006 Dickinson College Distinguished Alumni Award for Professional Achievement. This yearly award names alumni who have demonstrated outstanding accomplishment, as well as strength of character, in their professional and civic lives.

AWARDS (continued):

2006 CINP 2006 Lundbeck Neuroscience Foundation Prize for Education in Psychiatry and Neurology, one award given every 2 years for “education in psychiatry and neuroscience to an individual (or group) who has attained particularly valuable achievements in the field of postgraduate education in psychiatry and neuroscience.”

2005 First Annual Irma Bland Award for Excellence in Teaching Residents, given annually by the American Psychiatric Association to Departments of Psychiatry for outstanding and sustaining contributions made as a faculty.

2005 Paul Hoch Distinguished Service Award for Contributions to the College, presented by the American College of Neuropsychopharmacology

2004 Excellence in Teaching Award, Stanford University School of Medicine, Stanford, CA. In recognition of contributions to the educational mission of the school.

2004 Nominee for Franklin G. Ebaugh, Jr. Award for excellence in teaching, SUSM

2003 Metzger-Conway Fellow, Clarke Center, Dickinson College, Carlisle, PA

2003 Fulbright Lecturing Award, India

2002 Rockefeller Foundation Award for Residence at Bellagio, Italy, Summer 2002.

2001 Distinguished Contribution to Family Systems Research Award. This annual AFTA award recognizes an individual for outstanding research on subjects central to the field of family therapy.

2000 Annual Outstanding Achievement Award of the Northern California Psychiatric Society (NCPS) of the APA, “recognizes a member of NCPS who has made significant and exceptional contributions to the field of psychiatry.”

(More available upon request)

PUBLICATIONS:

Books, Monographs, Bibliographies:

1. Glick ID, Balon R (eds.): The American Society of Clinical Psychopharmacology Model Psychopharmacology Curriculum for *Medical Students*, ASCP, POB 40395, Glen Oaks, NY 11004, 2009.

2. Keitner G, Heru A, Glick I: Clinical Manual of Couples & Family Therapy. American Psychiatric Publishing, Inc., Arlington, VA, 322 pgs, 2010.

PUBLICATIONS (continued):

3. Tandon R, Glick ID, Goldman M, Jibson MD, Marder SR, Mellman TA: Managing Schizophrenia, A Comprehensive Primer 2005. McMahon Publishing Group, New York, 2005.
4. Ritvo EC, Glick ID: The Concise Guide to Marriage and Family Therapy. American Psychiatric Press, Inc. Washington, DC, 2002, pp. 1303-1327
2009 - Spanish Edition translated by Jose Luis Nunez Herrejon, Madrid, Manual Moderno pubs.
5. The ASCP Model Psychopharmacology Curriculum, for Psychiatric Residency Programs, Training Directors, and Teachers of Psychopharmacology. The American Society of Clinical Psychopharmacology, Inc., P.O. Box 40395, Glen Oaks, NY 11004. Glick ID (Editor of all four editions with a large committee for each edition) :
1999 – First Edition
2001 - Second Edition
2004 - Third Edition
2006 - Fourth Edition
2008 – Fifth Edition
• Invited Lectures: 1) Schizophrenia (with M. Jibson), 2) Combining Pharmacotherapy & Psychotherapy, 3) The Art of Psychopharmacology (with R. Balon)
6. DeBattista C, Glick ID (ed.). The Medical Management of Depression. Essential Medical Information Systems, Inc. Durant, OK: 1996.
1998 - Second Edition
2002 – Third Edition
7. Glick ID (ed): Treating Depression, San Francisco, Jossey-Bass, 1995.
2007 – Translated into Turkish by Yayin Dagitrin, Global Publishers.
8. Clarkin JF, Haas GL, Glick ID (eds): Affective Disorders and the Family: Assessment and Treatment, New York, Guilford Press, 1988.
9. Grunebaum H, Beavers WR, Berman E, Combrinck-Graham L, Glick ID, et al: (Formulated by the Committee on the Family, Group for the Advancement of Psychiatry), The Family, the Patient, and the Psychiatric Hospital: Toward a New Model. New York, Brunner/Mazel, 1985.

PUBLICATIONS (continued):

10. Glick ID, Janowsky DS, Salzman C, Shader RI: A Model Psychopharmacology Curriculum for Psychiatric Residents. Nashville, TN, The American College of Neuropsychopharmacology, 1984
a) Translated into Japanese, Japanese Journal of Psychopharmacology, 6:335-452, 1986
b) Reprinted in Psychopharmacology: The Third Generation of Progress, edited by Herbert Y. Meltzer. Raven Press, New York, 1313-1321, 1987
c) Translated into Japanese for the Lectures on Clinical Psychiatric Issues, Part II, edited by Yamaguchi T, Tajima S. Chugoku-shikoku Psychotherapy Workshops, Hiroshima and Nichidai Seishin-shinkeika Workshops, Tokyo 1994
11. Glick ID, Hargreaves WA: Psychiatric Hospital Treatment for the 1980s: A Controlled Study of Short Versus Long Hospitalization. Lexington, Mass., Lexington Press, 1979.
12. Glick ID, Kessler DR: Marital and Family Therapy. New York, Grune and Stratton, 1974
1976 - Summarized in Foote C, Levy RJ, Sander FEA, Cases and materials on family law, second edition, Boston, Little, Brown, 1976, pp. 1153-1145
1980 - Second Edition.
1985 - Translated into Japanese by Koji Suzuki, MD; 2nd printing, 1989
1986 - Translated into Chinese by Xiang De-Zhao, MD
1987 - Third Edition, with Clarkin JF & Kessler DR. Published by American Psychiatric Press, Inc., Washington, D.C.
2000 - Fourth Edition, with Berman E, Clarkin JF & Rait D. American Psychiatric Press, Inc., Washington, D.C.
2002 Spanish Edition, translated by Raquel Martin Lanas, Madrid, Grupo Medica
13. Glick ID, Haley J: Family Therapy and Research: An Annotated Bibliography of Articles and Books Published 1960-1970. New York, Grune and Stratton, 1971.
Glick ID, Weber D, Rubinstein D, Patten J: Family Therapy and Research: An Annotated Bibliography of Articles, Books, Videotapes and Films Published 1950-1979, 2nd Edition, New York, Grune and Stratton, 1982.
14. Haley J, Glick ID: Psychiatry and the Family, An Annotated Bibliography of Articles Published, 1960-64. Palo Alto, California, Family Process, 1965.

(Extended CV available upon request)